ImetelChat

Honestly? I do not answer to you. People in chat rooms don't get to make demands on others when it comes to their own analysis. When you questioned my integrity by saying I didn't really own GERN stock, I offered to prove my holdings but you just further attacked and actually accused me of being a l...

In response to the issue being posed here, I was responding to a question asking what would be the worst thing we could hear this week from the FDA. The question was subsequently deleted, making my post stand as a statement instead of an answer. I have since deleted it to avoid creating any panic or...

My wife and I have been patrons of the Sheldrick Trust for many years and she has even visited. The story of what they do there is an example of what the very best of humanity can accomplish. Unfortunately in many cases they are trying to undue that which is the very worst of humanity.

Seriously Kmall? Wow. Just wow.

Several months ago I did an analysis about the importance of the lead up to Phase 3 results versus the actual announcement of those results. The data suggested that the most significant share price increases occur 1 to 3 months before results are announced, followed by a modest increase at the time ...

So I think it could be very important to stratify—for instance, patients at the very beginning of their therapy—stratify in a way maybe that single agent luspatercept may be valid for as for a specific subset of patients who can stay on therapy for a long time, but may not be enough for another sti...

Here's the only part that really matters and constitutes our opportunity;

"Short of transplant, MF treatment is largely aimed at improving symptoms, splenomegaly, and quality of life."

In addition to the U.S., the two most recent trademarks have also been filed internationally in the following countries:

COUNTRY
European Union
COUNTRY
India
COUNTRY
Norway
COUNTRY
Switzerland
COUNTRY
United Kingdom
INTENTION TO USE
YES

According to the U.S. Patent and Trademark Office (USPTO), Geron Corp has filed the following trademarks for a commercial drug name. Seeing as Geron only has one drug in the pipeline (Imetelstat) I think that it's safe to say that these are the current contenders. I believe the newer ones are more l...

Great post that sums up the way I feel too. Scarlett has traditionally used the expression, "watch this space" and I always took that to mean, 'watch what we do, not just what we say'. One thing that I've been giving some thought to is that management expects significant proceeds to come in from war...

I mention it here in the interest of keeping THIS list current.

Nick Lyon was recently promoted to Senior Director, Head of CMC Regulatory.

https://www.linkedin.com/in/nick-lyon-246813b/

Agreed. I asked Dr. Scarlett in person during the last annual shareholder meeting before Covid about an oral version. He was adamant that it would require a return all the way back to Phase 1, so their emphasis was going to be on the transfused version until after FDA approval. We was quite gracious...

Back in 2011 2 different transfusions at 2 different hospitals for my wife were both billed about 150k included 7 days ICU for both....The insurance co paid about 50k to each billing, don't remember the breakdown of costs.....the third transfusion at the Mayo Clinic in Minn billed about 50k for sam...

BP- You make some great points but we can't forget that Imetelstat is a regular transfusion as well, so many of the costs you mentioned probably are replicated while on treatment. I do wonder though if these high transfusion burden patients take a disproportionate share of available blood bank resou...

It would be interesting to find out what the average cost of a transfusion is. In that way, we could look at the potential savings to insurance companies and compare it to what we believe Imetelstat will cost when commercialized. Of course the tricky bit is adjusting for the actual prices that insur...

Here's my current GERN position as of 11:06am EST on November 18, 2022. Now either demonstrate that you have a position in this stock or stop antagonizing me.

As the "shareholder" that has the "substantial" position you're referring to, I object to these thinly veiled comments you make about me. If you don't understand the wash sale rule and harvesting losses perhaps you are the one who should speak to an investment advisor. Where is the moderator when th...

Not everyone who owns GERN has purchased it in 2022. Several here (myself included) have owned shares for over 10 years. Some of my shares are underwater even at these levels. I have occasionally sold shares before a year ended to offset gains in other stocks I own. Then, after the 30 day wash sale ...

Only 3 weeks away from tax loss selling to be very dangerous.